Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bonnefoy, A.
Right arrow Articles by Le Priol, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonnefoy, A.
Right arrow Articles by Le Priol, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 471-473
© 2001 The British Society for Antimicrobial Chemotherapy

Brief report

Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics

Alain Bonnefoy,* and Pascal Le Priol

Aventis–Hoechst-Marion-Roussel, Infectious Diseases Group, 102 Route de Noisy, 93235 Romainville Cedex, France

Telithromycin (HMR 3647) is a ketolide suitable for the treatment of respiratory infections. The aim of this study was to demonstrate its antibacterial efficacy against an erythromycinsusceptible Staphylococcus aureus, an erythromycin-resistant Streptococcus pneumoniae and Haemophilus influenzae. The free serum concentrations of telithromycin, produced by repeated oral administration of 800 mg to adults for 10 days, was simulated in an in vitro system. The ketolide displayed bacteriostatic activity against all three strains tested. This study supported the observation that an 800 mg po dose of telithromycin demonstrated antibacterial efficacy against respiratory tract pathogens.

* Corresponding author. Tel: +33-1-4991-4778; Fax: +33-1-4991-5061; E-mail: Alain.Bonnefoy{at}Aventis.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
L. Kolilekas, G. K Anagnostopoulos, I. Lampaditis, and I. Eleftheriadis
Potential Interaction Between Telithromycin and Warfarin
Ann. Pharmacother., September 1, 2004; 38(9): 1424 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Okamoto, S. Miyazaki, K. Tateda, Y. Ishii, and K. Yamaguchi
In Vivo Efficacy of Telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae
Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3250 - 3252.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.